Tabuk Pharmaceuticals to manufacture four Pfizer products

June 30, 2014 5:57 am

Saudi-based Tabuk Pharmaceuticals has said it has signed a commercial agreement with Pfizer, the US-based global industry leader, Arab News has reported. The deal aims to deliver increased value to patients in the cardiovascular, central nervous system, anti-infective and respiratory therapeutic areas. Under the agreement, Pfizer will grant Tabuk exclusive rights to carry out manufacturing processes under licence, commercialise and distribute second brand versions of four Pfizer products in the kingdom.